Author

D. L. Goode

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Research Focus:drug response / drug discovery· 2 Approach:statistical model· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:chromatin & epigenetic regulation· 1 Assay:clinical cohort / trial· 1 Research Focus:clustering· 1

Frequent Co-Authors

A. S. Trigos· 2 shared R. B. Pearson· 2 shared A. Bakshi· 1 shared A. Clark· 1 shared A. Ryan· 1 shared A. T. Papenfuss· 1 shared B. Phipson· 1 shared C. Cullinane· 1 shared

Activity by Year

2018-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 18 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. S. Trigos

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Defining focal neuroendocrine differentiation as a transcriptionally distinct form of prostate cancer pathology characterized by the expression of androgen receptors

R. Quezada Urban, S. Keerthikumar, A. Clark, H. Wang, B. Phipson, A. Bakshi, A. Ryan, H. J. Thorne, R. A. Taylor, M. G. Lawrence, G. P. Risbridger, R. Toivanen, D. L. Goode

This study uses single-cell RNA sequencing to show that focal neuroendocrine differentiation (Focal NED) in prostate cancer is transcriptionally distinct, characterized by androgen receptor expression and unique transcriptional sub-populations.

bioRxiv · Mar 17, 2024 · PreprintCancer Biology

Reprogrammed mRNA translation drives resistance to therapeutic targeting of ribosome biogenesis

E. P. Kusnadi, A. S. Trigos, C. Cullinane, D. L. Goode, O. S. Larsson, J. R. Devlin, K. T. Chan, D. P. DeSouza, M. J. McConville, G. A. McArthur, G. Thomas, E. Sanij, G. Poortinga, R. D. Hannan, K. M. Hannan, , R. B. Pearson

The paper shows that combining CX-5461 with pathway inhibitors improves efficacy by suppressing metabolic regulators, but resistance arises through translational re-wiring and cAMP pathway activation in blood cancers.

bioRxiv · Mar 26, 2020Cancer Biology

Somatic mutations in early metazoan genes disrupt regulatory links between unicellular and multicellular genes in cancer

A. S. Trigos, R. B. Pearson, A. T. Papenfuss, D. L. Goode

The paper identifies somatic mutations in early metazoan genes that disrupt regulatory links between unicellular and multicellular genes in cancer, linking these mutations to drug response.

bioRxiv · Aug 9, 2018Cancer Biology